Specifically targeting ERK1 or ERK2 kills Melanoma cells

Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression

(2011) J Lin et al.   BRITISH JOURNAL OF CANCER

Latest developments in the treatment of melanoma: ‘a penicillin moment for cancer’?

(2011) Spyros Retsas   JOURNAL OF THE ROYAL SOCIETY OF MEDICINE

Biological challenges of BRAF inhibitor therapy

(2011) Igor Puzanov et al.   Molecular Oncology

Vemurafenib

(2011) Keith. T Flaherty et al.   NATURE REVIEWS DRUG DISCOVERY

Resistance to BRAF Inhibition in Melanomas

(2011) David B. Solit et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the RAS pathway in melanoma

(2011) Zhenyu Ji et al.   TRENDS IN MOLECULAR MEDICINE

The “SWOT” of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?

(2011) Moriah H. Nissan et al.   Current Oncology Reports

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

(2010) K H T Paraiso et al.   BRITISH JOURNAL OF CANCER

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

An ERK-dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs

(2010) C Sheridan et al.   ONCOGENE

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Increasing Burden of Melanoma in the United States

(2009) Eleni Linos et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

(2009) C. A. Pratilas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MAP kinase: It’s been longer than fifteen minutes

(2008) Thomas W. Sturgill   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Is B-Raf a Good Therapeutic Target for Melanoma and Other Malignancies?

(2008) S. V. Madhunapantula et al.   CANCER RESEARCH

BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins

(2008) B. B. Friday et al.   CANCER RESEARCH

Tumour cell survival signalling by the ERK1/2 pathway

(2008) K Balmanno et al.   CELL DEATH AND DIFFERENTIATION